Introduction: Biosimilars in Rheumatology Consensus

In order to prepare a League position document on biosimilars in rheumatology, with a methodology that ensures transparency, objectivity and balance in accordance with its mission, we clinical specialists and methodologists have been working in the exhaustive review of the literature to answer the following main questions concerning their use:

  • Complexities in their fabrication: Indications and extrapolations of the same
  • Substitution or interchangeability
  • Immunogenicity and safety
  • Pharmacovigilance
  • Economical aspects of biosimilars
  • Final amendments and signing of the document

All the national and regional associations were invited to select their delegates, which resulted in a group of very high level and internationally recognized panelists; in addition, we assembled a group of experts to advise the consensus, which gives us assurance that the uncertainties on this topic will be addressed and that we will receive a position document that will guide clinicians, regulatory entities and public policy makers in improving access to medication and healthcare quality.

Aside from learning about this relevant topic, every participant rheumatologist in the course will get to know the results of the consensus and the PANLAR position document, and will be able to immediately use this information to the benefit of his/her patients.

Claudio Galarza Maldonado
Biosimilars in Rheumatology Consensus Coordinator